Datapoint: Incyte Scores Merkel Cell Carcinoma Nod for Zynyz
The FDA last week approved Incyte Corp.’s Zynyz for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC), a rare form of skin cancer. The PD-1 inhibitor will join oncology heavyweights in MCC market basket — Merck’s Keytruda and Bristol Myers Squibb’s Opdivo. Under the medial benefit, Opdivo is currently the most advantaged MCC therapy, holding covered or better status for 89% of all insured lives. Keytruda follows closely behind at 88%.
SOURCE: MMIT Analytics, as of 3/27/23